Clinical trial
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2…
NCT00326326 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00326326 |
|---|---|
| Title | Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes. |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dyslipidemia |
| Intervention type | Drug |
| Interventions | CP-778, 875 |
| Enrollment | 84 |
| Start date | Jul 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | May 7, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: